Increased Copper in Individuals with Autism Normalizes Post Zinc Therapy More Efficiently in Individuals with Concurrent GI Disease

Nutrition and Metabolic Insights

Volumn 4, Issue , 2011, Pages

  Russo, Anthony J ^a,b  

^a HARTWICK COLLEGE   (United States)

^b Pfeiffer Treatment Center   (United States)

Author keywords

autism; copper; zinc

Indexed keywords

EID: 84990050795     PISSN: None     EISSN: 11786388     Source Type: Journal    
DOI: 10.4137/NMI.S6827     Document Type: Article

References (60)

1. Muhle R., Trentacoste S.V., Rapin I. The genetics of autism. Pediatrics. 2004; 113: e472–86.
2. Yeargin-Allsopp M., Rice C., Karapurkar T., Doernberg N., Boyle C., Murphy C. Prevalence of autism in a US metropolitan area. J Am Med Assoc. 2003; 289: 49–55.
3. Schanen C.N. Epigenetics of autism spectrum disorders. Human Molecular Genetics. 2006; 15: 138–50.
4. Fombonne E. Epidemiological surveys of autism and other pervasive developmental disorders: an update. J Autism Dev Disord. 2003; 33: 365–82.
5. Barrett S., Beck J.C., Bernier R. et al. An autosomal genomic screen for autism. Collaborative linkage study of autism. Am J Med Genet. 1999; 88: 609–15.
6. International Molecular genetics study of autism consortium. Further characterization of the autism susceptibility locus AUTS1 on chromosome 7q. Hum Mol Genet. 2001; 10: 973–82.
7. Yonan A.L., Alarcon M., Cheng R. et al. A genomewide screen of 345 families for autism-susceptibility loci. Am J Hum Genet. 2003; 73: 886–97.
8. Hutcheson H.B., Olson L.M., Bradford Y. et al. Examination of NRCAM, LRRN3, KIAA0716, and LAMB1 as autism candidate genes. BMC Med Genet. 2004; 5: 12.
9. Valicenti-McDermott M., McVicar K., Rapin I., Wershil B.K., Cohen H., Shinnar S. Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. J Dev Behav Pediatr. 2006; 27: S128–36.
10. Jyonouchi H., Geng L., Ruby A., Zimmerman-Bier B. Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology. 2005; 51: 77–85.
11. White J.F. Intestinal pathophysiology in autism. Exp Biol Med (Maywood). 2003; 228: 639–49.
12. Russo A.J., Krigsman A., Jepson B., Wakefield A. Low serum Alpha-1 Antitrypsin Associated with Anti-PR3 ANCA in Autistic children with GI Disease. Genomics Insights. 2009; 2: 1–9.
13. Russo A.J., Krigsman A., Jepson B., Wakefield A. Anti-PR3 and anti-MPO IgG ANCA in autistic children with chronic GI disease. Immunology and Immunogenetics Insights. 2009; 2: 21–8.
14. Russo A.J. Anti-Metallothionein IgG and levels of metallothionein in autistic families. Swiss Med Weekly. 2008; 138(5-6): 70–7.
15. Russo A.J. Anti-metallothionein IgG and levels of metallothionein in autistic children with GI disease. Drug, Healthcare and Patient Safety. 2009; 1: 1–8.
16. Raulin J. Etudes clinique sur la vegetation. Annales des Scienceas Naturelle: Botanique. 1869; 11: 93–299.
17. Maze P. Influences respectives des elements de la solution gmineral du mais. Annales de l'Institut Pasteur (Paris). 1914; 28: 21–69.
18. Todd WR, Elvehjem C.A., Hart E.B. Zinc in the nutrition of the rat. American Journal of Physiology. 1934; 107: 146–56.
19. Vallee B.L., Auld D.S. Zinc coordination, function, and structure of zinc enzymes and other proteins. Biochemistry. 1990; 29: 5647–59.
20. Miller W.J., Blackmon D.M., Gentry R.P., Pitts W.J., Powell G.W. Absorption, excretion, and retention of orally administered zinc-65 in various tissues of zinc-deficient and normal goats and calves. Journal of Nutrition. 1967; 92: 71–8.
21. Brown R.S., Sander C., Argos P. The primary structure of transcription factor IIIA has 12 consecutive repeats. FEBS Letters. 1985; 186: 271–4.
22. McNulty T.J., Taylor C.W. Extracellular heavy- metal ions stimulate Ca2+ mobilization in hepatocytes. Biochemical Journal. 1999; 339(Pt 3): 555–61.
23. Zalewski P.D., Forbes I.J., Betts W.H. Correlation of apoptosis with change in intracellular labile Zn(II) using zinquin [(2-methyl-8-p-toluenesulphonamido-6 quinolyloxy)acetic acid], a new specific fluorescent probe for Zn(II). Biochemical Journal. 1993; 296: 403–8.
24. Prasad A.S. Clinical manifestations of zinc deficiency. Annual Review of Nutrition. 1985; 5: 341–63.
25. Cunnane S.C. Role of zinc in lipid and fatty acid metabolism and in membranes. Progress in Food and Nutrition Science. 1988; 12: 151–88.
26. Endre L., Katona Z., Gyurkovits K. Zinc deficiency and cellular immune deficiency in acrodermatitis enteropathica. Lancet. 1975; 2: 119–6.
27. Aggett P.J. Acrodermatitis enteropathica. Journal of Inherited Metabolic Disease. 1983; 1: 39–43.
28. Halsted J.A., Ronaghy H.A., Abadi P. Zinc deficiency in man. American Journal of Medicine. 1972; 53: 277–84.
29. Prasad A.S. Role of zinc in human health. Boletin de la Asociacion Medica de Puerto Rico. 1991; 83: 558–60.
30. Vallee B.L., Falchuk K.H. The biochemical basis of zinc physiology. Physiological Reviews. 1993; 73: 79–118.
31. Hambidge M. Human zinc deficiency. J Nutr. 2000; 130(5S Suppl): 1344S–9.
32. Ho E., Ames B. Low intracellular zinc induces oxidative DNA damage, disrupts p53, NFΚB, and AP1 DNA binding, and affects DNA repair in a rat glioma cell line. Proc Natl Acad Sci USA. 2002; 99(26): 16770–5.
33. Song Y. et al. Zinc deficiency affects DNA damage, oxidative stress, antioxidant defenses, and DNA repair in rats. Journal of Nutrition. 2009; 139: 1626–31.
34. Powell S. The Antioxidant properties of zinc. Journal of Nutrition. 2000; 130: 1447S–54.
35. Vassiliev V., Harris Z.L., Zatta P. Ceruloplasmin in neurodegenerative diseases. Brain Res Rev. 2005; 49: 633–40.
36. Arnaud P., Gianazza E., Miribel Ceruloplasmin L. Methods Enzymol. 1988; 163: 441–52.
37. Horn N., Tonnesen T., Tumer Z. Menkes disease: an X-linked neurological disorder of the copper metabolism. Brain Pathol. 1992; 2: 351–62.
38. Wendland B.E., Greenwood C.E., Weinberg I., Young K.W. Malnutrition in institutionalized seniors: the iatrogenic component. J Am Geriatr Soc. 2003; 51: 85–90.
39. Kumar N. Copper deficiency myelopathy (human swayback). Mayo Clin. Proc. 2006; 81: 1371–84.
40. Kassu A.T., Yabutani Z.H., Mahmud A. et al. Alterations in serum levels of trace elements in tuberculosis and HIV infections. Eur J Clin Nutr. 2006; 60: 580–6.
41. Ko W.S., Guo C.H., Yeh M.S. et al. Blood micronutrient, oxidative stress and viral load in patients with chronic hepatitis C. World J Gastroenterol. 2005; 11: 4697–702.
42. Molteni A., Ward W.F., Kim Y.T. et al. Serum copper concentration as an index of clinical lung injury. Adv Exp Med Biol. 1989; 258: 273–85.
43. Das S.K., Ray K. Wilson's disease: an update. Nat Clin Pract Neurol. 2006; 2: 482–93.
44. Wapnir R.A. Copper absorption and bioavailability. Am J Clin Nutr. 1998; 67: 141–3.
45. Yilmaz A., Sari R.A., Gundogdu M., Kose N., Dag E. Trace elements and some extracellular antioxidant proteins levels in serum of patients with systemic lupus erythematosus. Clin Rheumatol. 2005; 24: 331–5.
46. Chauhan A. et al. Increased copper-mediated oxidation of membrane phosphatidylethanolamine in autism. American Journal of Biochemistry and Biotechnology. 2008; 4(2): 95–100.
47. Collins A. et al. Investigation of autism and GABA receptor subunit genes in multiple ethnic groups. Neurogenetics. 2006; 7(3): 167–74.
48. Ma D.Q. et al. Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism. Am J Hum Genet. 2005; 77(3): 377–88.
49. Ashley-Koch A.E. et al. An analysis paradigm for investigating multi-locus effects in complex disease: examination of three GABA receptor subunit genes on 15q11-q13 as risk factors for autistic disorder. Ann Hum Genet. May 2006; 70(Pt 3): 281–92.
50. Xie X., Smart T. Properties of GABA-mediated synaptic potentials induced by zinc in adult rat hippocampal pyramidal neurones. J Physiol. 1993; 460: 503–23.
51. Ben-Ari Y., Cherubini E. Zinc and GABA in developing brain. Nature. 1991; 353: 220.
52. Takeda A., Hirate M., Tamano H., Oku N. Release of glutamate and GABA in the hippocampus under zinc deficiency. J Neurosci Res. 2003; 72(4): 537–42.
53. Takeda A., Itoh H., Imano S., Oku N. Impairment of GABAergic neurotransmitter system in the amygdala of young rats after 4-week zinc deprivation. Neurochem Int. 2006; 49(8): 746–50.
54. Sharonova I.N., Vorobjev V.S., Haas H.L. High-affinity copper block of GABA(A) receptor-mediated currents in acutely isolated cerebellar Purkinje cells of the rat. Eur J Neurosci. 1998; 10(2): 522–8.
55. A receptors. Molecular Pharmacology. 2003; 64: 1145–52.
56. Lake C.R., Ziegler M.G., Murphy D.L. Increased norepinephrine levels and decreased dopamine-beta-hydroxylase activity in primary autism. Arch Gen Psychiatry. May 1977; 34(5): 553–6.
57. Rahman K. et al. Dopamine-β-hydroxylase (DBH), its cofactors and other biochemical parameters in the serum of neurological patients in Bangladesh. Int J Biomed Sci. 2009; 5(4): 395–401.
58. Deinum J. et al. DBH gene variants that cause low plasma dopamine β hydroxylase with or without a severe orthostatic syndrome. J Med Genet. 2004; 41: e38 doi: 10.
59. Prasad A.S. The role of zinc in gastrointestinal and liver disease. Clin Gastroenterol. Sep 1983; 12(3): 713–41.
60. Prasad A.S. Clinical manifestations of zinc deficiency. Annu Rev Nutr. 1985; 5: 341–63.